(-)-Cevimeline hydrochloride risodium salt Smiles: CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC1=NC(=NC(OCC(O)CO)=C1OC1=CC=CC=C1OC)C1=CC=C(C=C1)OC

Smiles: CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC1=NC(=NC(OCC(O)CO)=C1OC1=CC=CC=C1OC)C1=CC=C(C=C1)OC

75-47-43(67)39(63)37(61)29(72-47)22-69-45-41(65)34(58)26(57)21-68-45)24-11-16-52(7)33(24)25(56)18-31-50(5)15-13-32(49(3

553(Pt 2):627-35

Co-incubation of pulmonary arterial smooth muscle cells (PASMCs) from the pulmonary arterial hypertension (PAH) rats with UK-92480 and LDN193189 completely inhibited the anti-proliferation and up-regulation of the bone morphogenetic protein (BMPR2) and Cx40 expression by the UK-92480

(-)-Cevimeline hydrochloride risodium salt Smiles: CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC1=NC(=NC(OCC(O)CO)=C1OC1=CC=CC=C1OC)C1=CC=C(C=C1)OC( ) Cevimeline hydrochloride hemihydrate (( ) SNI 2011), a novel muscarinic receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other tissues were investigated in mice, rats, guinea pigs, rabbits, and dogs. The in vitro metab. of SNI 2011 was also evaluated with rat and dog liver